<DOC>
	<DOCNO>NCT02000375</DOCNO>
	<brief_summary>A phase II non randomize study evaluate role Androgen Receptors Targets therapy pre-treated postmenopausal patient ER/PgR-negative/AR-positive ER and/or PgR-positive/AR-positive metastatic breast cancer . Study Design : Multicentric , Open-label randomize trial . Description Study Treatment : Daily oral administration DHEA ( Dehydroepiandrosterone ) dosage 100 mg/die combination daily oral administration anastrozole dosage 1 mg/die letrozole dosage 2.5 mg/die exemestane dosage 25 mg/die without interruption discontinuation progression disease , unacceptable toxicity discontinuation/withdrawal participant study treatment . Number Subjects : 12 patient per group first step ; number responder great equal 2 , recruitment continue total 35 patient ( per group ) . For biological part , evaluate : 1 . Correlation AR expression clinical biological feature ( tumor size , nodal status , histotype , grading , proliferative index , ER , PgR , HER2 ) 2 . Evaluation AR expression primitive and/or metastatic site two distinct population patient : ER/PgR- negative/ARpositive ER-positive and/or PgR-positive/AR-positive 3 . Evaluation ER , PgR , HER2 expression tumor cell metastatic site ( possible ) comparison feature primitive tumor . 4 . CTCs analysis term molecular characteristic ( gene expression mutation ) functionality ( vitality tumorigenicity ) . 5 . Prognostic predictive role Circulating Tumor Cells ( CTC ) evaluate baseline study treatment moment discontinuation treatment .</brief_summary>
	<brief_title>A Phase II Study Evaluating Role Androgen Receptors Targets Therapy Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer ( ARTT )</brief_title>
	<detailed_description>A phase II non randomize study evaluate role Androgen Receptors Targets therapy pre-treated postmenopausal patient ER/PgR-negative/AR-positive ER and/or PgR-positive/AR-positive metastatic breast cancer . Study Design : Multicentric , Open-label randomize trial . Description Study Treatment : Daily oral administration DHEA ( Dehydroepiandrosterone ) dosage 100 mg/die combination daily oral administration anastrozole dosage 1 mg/die letrozole dosage 2.5 mg/die exemestane dosage 25 mg/die without interruption discontinuation progression disease , unacceptable toxicity discontinuation/withdrawal participant study treatment . Number Subjects : 12 patient per group first step ; number responder great equal 2 , recruitment continue total 35 patient ( per group ) . For biological part , evaluate : 1 . Correlation AR expression clinical biological feature ( tumor size , nodal status , histotype , grading , proliferative index , ER , PgR , HER2 ) 2 . Evaluation AR expression primitive and/or metastatic site two distinct population patient : ER/PgR- negative/ARpositive ER-positive and/or PgR-positive/AR-positive 3 . Evaluation ER , PgR , HER2 expression tumor cell metastatic site ( possible ) comparison feature primitive tumor . 4 . CTCs analysis term molecular characteristic ( gene expression mutation ) functionality ( vitality tumorigenicity ) . 5 . Prognostic predictive role Circulating Tumor Cells ( CTC ) evaluate baseline study treatment moment discontinuation treatment . Statistical Considerations : The sample size require treatment arm predict use SIMON two-stage design 10 percent alpha beta error . Assuming acceptable minimum clinical benefit P0 equal 10 percent auspicious clinical benefit P1 equal 30 percent , plan recruit 12 patient per group first step . If number responder great equal 2 , recruitment continue total 35 patient ( per group ) . If number responder great equal 6 , combination consider active worthy evaluation . If subgroup population discontinue end first step , study continue subgroup .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>1 . Histologicaldocumented diagnosis invasive breast cancer . 2 . Clinical diagnosis metastatic breast cancer . 3 . AR receptor positivity primary tumor cell tumor cell metastatic site require . It strongly recommend 4 unstained freshly cut 34 μ slide primary tumor ( metastatic primary available ) submit IRCCS IRST Laboratorio di Bioscienze confirmation AR eligibility ; however , possible , formalinfixed paraffinembedded ( FFPE ) tissue block submit . Tumors ≥10 % positively nuclearstained cell immunohistochemistry ( IHC ) consider positive AR . 4 . Primary tumor cell tumor cell metastatic site ERpositive and/or PgRpositive ERnegative/PgRnegative . Hormone receptor positivity define ER and/or PgR great 10 fmol/mg biochemical assay great equal 10 percent positive cell immunohistochemistry . 5 . Primary tumor cell tumor cell metastatic site must HER2 negative . 6 . Measurable disease , define accord RECIST criterion ( version 1.1 ) 1. least one lesion accurately measure least one dimension ( long diameter record ) &gt; 10 mm CT scan MRI ( slice thickness grater 5 mm . If slice thickness grater 5 mm minimum size miserable lesion baseline twice slice thickness baseline scan ) 2. consider pathologically enlarge measurable , lymph node must ≥ 15 mm short axis assess CT scan MRI ( slice thickness grater 5 mm . If slice thickness grater 5 mm minimum size miserable node baseline ) . 7 . In case ERpos disease , previous endocrine treatment adjuvant metastatic setting required patient must resistant aromatase inhibitor mean : AI adjuvant setting : patient treat least 1 year recurrence treatment first year finish adjuvant treatment AI advance disease : patient must receive AI last least 6 month , patient must achieve tumor response stabilization , objective progression treatment 8 . No 2 previous line chemotherapy ERpos tumor 3 line chemotherapy ERneg tumor allow 9 . Postmenopausal status define : 1 . Patients age bilateral oophorectomy ( include radiation castration ) 2 . Patients 56 year old old . If patient evidence ovarian function , biochemical evidence definite postmenopausal status ( define estradiol , LH , FSH postmenopausal range ) require . 3 . Patients 55 year old young without period last 12 month biochemical evidence definite postmenopausal status ( define estradiol , LH , FSH postmenopausal range ) . 10 . At least 18 year age 11 . Life expectancy great 12 week 12 . ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 13 . Adequate organ marrow function define : leukocyte &gt; 3,000/mL absolute neutrophil count &gt; 1,500/mL platelet &gt; 100,000/mL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional ULN creatinine within normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal 14 . Patients must exhibit capability swallow tablet 15 . Patients must exhibit compliance oral treatment 16 . Patients must exhibit geographic proximity allow regular access Institute clinical instrumental examination require 17 . Participants must willing able give inform consent participation study . 1 . ARreceptor negativity primary tumor cell tumor cell metastatic site . AR report negative less 10 % cell immunostained tumor . 2 . HER2 positivity primary tumor cell tumor cell metastatic site 3 . Physician opinion rapid disease progression ( like disease widespread visceral organ like liver lung month ) could suggest physician benefit chemotherapy treatment even eligibility criterion enrollment satisfied 4 . Chemotherapy administration within 3 week prior start protocol therapy recover adverse event due agent administer 3 week earlier 5 . Brain metastasis treated progression require treatment ( radiotherapy , surgery high dose steroidal antiedemigen treatment ) 2 week prior start protocol therapy . Patients brain metastasis unique site metastasis exclude 6 . Have receive supplement estrogen progesterone within 4 week prior study enter 7 . Major surgery 21 day start protocol therapy plan study treatment 8 . Other detectable malignant neoplastic disease ( even second primitive breast cancer ) patient 's medical history diseasefree interval le 5 year ( except previously treat basal cell carcinoma skin situ carcinoma uterine cervix ) 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 10 . Participation another clinical trial investigational agent within 3 week prior study screen 11 . Previous treatment androgen DHEA . Previous treatment AI require case ER+ and/or PgR positive tumor 12 . History allergic reaction attribute compound similar chemical biologic composition DHEA AI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>metastatic breastcancer</keyword>
	<keyword>ER/PgR-negative/AR-positive</keyword>
	<keyword>ER and/or PgR-positive/AR-positive</keyword>
	<keyword>Androgen Receptor positve</keyword>
</DOC>